Products for Research Use Only
RegisterLogin

AZ13705339

CAT: 0804-HY-120940-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120940-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AZ13705339 is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers[1].
CAS Number
2016806-57-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PAK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/az13705339.html
Purity
98.57
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
N#CC1=CC=CC=C1CN(C2=NC(NC3=CC=C(N4CCN(C)CC4)C(S(=O)(CC)=O)=C3)=NC=C2F)C5=CC(CO)=CC=C5C
Molecular Formula
C33H36FN7O3S
Molecular Weight
629.75
Precautions
H302, H315, H319
References & Citations
[1]McCoull W, Hennessy EJ, Blades K, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016;7 (12) :1118-1123. Published 2016 Sep 14.|[2]Martin F M de Rooij, et al. A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nat Commun. 2022 Apr 19;13 (1) :2136. |[3]Daniela J Carroll, et al. Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro. Front Immunol. 2021 Oct 11;12:737988.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PAK1; PAK2

Alternative Products

CatalogName
BA4355-25AZ13705339
T72321-01AZ13705339 hemihydrate

Popular Products